ASGE Annual GI Advanced Practice Provider Course (On-Demand) - Clinical Case-Based Learning (Day Two) | March 2024-IBD Pharmacology Update

Pdf Summary

The document discusses updates in inflammatory bowel disease (IBD) pharmacology, presented by Kimberly Kearns from DULY Health and Care. It covers various topics including the differentiating features of Crohn's Disease and Ulcerative Colitis, guiding principles of IBD management, and updates on new pharmacological treatments such as Biologics like Mirikizumab and Etrasimod, as well as JAK inhibitors and biosimilars. Safety considerations, dosing schedules, and monitoring requirements for these treatments are also highlighted. The importance of early treatment in managing IBD is emphasized along with patient-specific considerations influencing the safety profile of IBD drugs. Additionally, the notion of biosimilars and strategies for their effective use are detailed, focusing on factors that guide the selection of the right treatment for individual patients. The document concludes with practice pearls reiterating the importance of patient-centered decision-making in IBD treatment.

Asset Subtitle

Kimberly Kearns, MS, APN-BC

Meta Tag

Concept Crohn Disease

Concept Ulcerative Colitis

Concept Inflammatory Bowel Disease

Concept Risk Stratification

Concept Biosimilars

Keywords

inflammatory bowel disease

pharmacology

IBD management

Biologics

safety considerations

dosing schedules

monitoring requirements

biosimilars

patient-specific considerations

patient-centered decision-making

Crohn Disease

Ulcerative Colitis

Inflammatory Bowel Disease

Risk Stratification

Biosimilars